Legend Biotech to present LB2501 in vivo CAR-T data at EHA conference

June 2, 2026 9:30 AM

Legend Biotech Corporation (NASDAQ: LEGN) will present Phase 1 clinical data for its investigational therapy LB2501 at the European Hematology ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found